
Synthetic Biologics SYN
Quartalsbericht 2025-Q3
hinzugefügt 12.11.2025
Synthetic Biologics Kurshistorie 2011-2026 | SYN
Kurshistorie Jährlich Synthetic Biologics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.96 | 0.96 | 0.96 | 0.24 | 0.67 | 0.43 | 0.64 | 12.6 | 27.6 | 67.2 | 81.2 | 94.5 | 60.2 | 76.7 |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 94.5 | 0.24 | 30.3 |
Kurshistorie anderer Aktien in der Pharmaeinzelhändler
| Name | Kurshistorie | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Aquestive Therapeutics
AQST
|
4.37 | $ 4.12 | -0.36 % | $ 441 M | ||
|
MorphoSys AG
MOR
|
18.2 | - | 2.43 % | $ 254 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
7.93 | $ 8.32 | 3.67 % | $ 228 M | ||
|
Arcutis Biotherapeutics
ARQT
|
27.1 | $ 23.65 | 0.08 % | $ 3.01 B | ||
|
BioVie
BIVI
|
1.65 | $ 1.46 | 2.82 % | $ 2.16 M | ||
|
BioLineRx Ltd.
BLRX
|
2.65 | $ 2.32 | 4.98 % | $ 908 M | ||
|
BioNTech SE
BNTX
|
91.2 | $ 91.44 | 0.29 % | $ 27.2 B | ||
|
I-Mab
IMAB
|
0.68 | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
3.36 | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
0.33 | - | -13.47 % | $ 169 M | ||
|
BioXcel Therapeutics
BTAI
|
1.26 | $ 1.16 | -2.12 % | $ 14.2 M | ||
|
Midatech Pharma plc
MTP
|
0.29 | - | -18.52 % | $ 27.3 M | ||
|
Burford Capital Limited
BUR
|
10.6 | $ 4.52 | 9.18 % | $ 683 M | ||
|
Acorda Therapeutics
ACOR
|
13.5 | - | -24.86 % | $ 820 K | ||
|
Cabaletta Bio
CABA
|
2.82 | $ 3.1 | 4.56 % | $ 311 M | ||
|
Adverum Biotechnologies
ADVM
|
3.86 | - | - | $ 86.2 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.45 | $ 3.17 | 1.44 % | $ 6.9 B | ||
|
Advaxis
ADXS
|
0.31 | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
0.57 | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
5.72 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
13 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
3.17 | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
12 | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.3 | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
48.4 | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
5.34 | - | 0.23 % | $ 488 M | ||
|
Catalyst Biosciences
CBIO
|
11.2 | $ 19.48 | 0.39 % | $ 1.74 B | ||
|
Allena Pharmaceuticals
ALNA
|
0.383 | - | 3.16 % | $ 1.9 M | ||
|
Codexis
CDXS
|
1.27 | $ 1.95 | 6.87 % | $ 170 M | ||
|
Alpine Immune Sciences
ALPN
|
8.04 | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
2.13 | - | 10.36 % | $ 9.8 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
3.41 | $ 3.01 | 0.67 % | $ 257 M | ||
|
Cerus Corporation
CERS
|
2.6 | $ 1.91 | 2.69 % | $ 364 M | ||
|
Cullinan Management
CGEM
|
14.9 | $ 15.11 | 4.71 % | $ 910 M | ||
|
Coherus BioSciences
CHRS
|
1.93 | $ 1.72 | -0.87 % | $ 201 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
2.46 | $ 0.46 | -13.02 % | $ 5.27 M | ||
|
Aravive
ARAV
|
1.66 | - | -13.39 % | $ 1.45 M | ||
|
Aptose Biosciences
APTO
|
3.32 | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
0.14 | - | -39.0 % | $ 4.57 M | ||
|
CNS Pharmaceuticals
CNSP
|
2.39 | $ 2.25 | -0.44 % | $ 998 K | ||
|
CureVac N.V.
CVAC
|
19.3 | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
74.2 | - | - | $ 96.9 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
24.9 | $ 24.95 | 1.05 % | $ 3.05 B | ||
|
Celldex Therapeutics
CLDX
|
30.7 | $ 31.33 | 0.85 % | $ 2.08 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
9.55 | $ 10.27 | 0.98 % | $ 137 M | ||
|
Cardiff Oncology
CRDF
|
1.74 | $ 1.6 | 1.27 % | $ 107 M | ||
|
Avenue Therapeutics
ATXI
|
0.42 | - | -52.27 % | $ 4.45 M |